Twist Bioscience FY26 net loss widens 68% year over year to $130.2 million; FY26 revenue rises 22% year over year to $459.4 million

PUBT · 2d ago
Twist Bioscience FY26 net loss widens 68% year over year to $130.2 million; FY26 revenue rises 22% year over year to $459.4 million
  • Twist Bioscience's Q4 FY26 net loss narrowed 24% year-over-year to $20.6 million; revenue rose 28% to $126.6 million.
  • FY26 net loss widened 68% year-over-year to $130.2 million; revenue climbed 22% to $459.4 million.
  • Cash, cash equivalents and short-term investments totaled approximately $582 million at September 30, 2026, following approximately $425 million in equity proceeds.
  • New launches included Twist Express Screening Antibodies and Twist MRD Express custom panels, offering turnaround times of as little as one day.
  • FY27 revenue guidance targets $550 million to $560 million, with first-quarter revenue projected at $130 million to $132 million.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Twist Bioscience Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001581280-26-000053), on November 12, 2026, and is solely responsible for the information contained therein.